Publications by authors named "Gordon Searles"
Article Synopsis
- The treat-to-target (T2T) strategy is increasingly used in medicine for optimal treatment decisions and may be effective for managing IL-17 inhibitors in autoimmune diseases like psoriasis, psoriatic arthritis, and ankylosing spondylitis.
- The article aims to evaluate the effectiveness and safety of IL-17 inhibitors using the T2T approach based on clinical trial evidence.
- Results indicate that IL-17 inhibitors like secukinumab and ixekizumab significantly outperform placebo and improve outcomes for psoriasis, psoriatic arthritis, and ankylosing spondylitis, with low rates of serious side effects.
Health literacy refers to the comprehension required to make well-informed decisions regarding one's health. It is a critical component in helping patients to understand how to take their medications appropriately. However, many patients do not possess the comprehension necessary for medication adherence.
View Article and Find Full Text PDFBackground: Non-melanoma skin cancer (NMSC), including basal and squamous cell carcinoma, represents the most common malignancy.
Objective: The aim of this document is to provide guidance to Canadian health care practitioners on NMSC management.
Methods: After conducting a literature review, the group developed recommendations for prevention, management, and treatment of basal cell carcinomas, squamous cell carcinomas, and actinic keratoses.
Objective: Explore the feasibility of Treat to Target in the area of psoriasis as seen in other therapeutic areas such as hypertension, hyperlipidemia, diabetes and rheumatoid arthritis.
Methods: Review validated, measurable targets for psoriasis, including physician global assessment (PGA), psoriasis area and severity index (PASI) and dermatology life quality index (DLQI). Examine principles brought forth in the published European consensus on psoriasis and develop a Canadian consensus on Treat to Target in psoriasis.
Background: Non-melanoma skin cancer (NMSC), including basal and squamous cell carcinoma (BCC and SCC), represents the most common malignancy.
Objective: To provide guidance to Canadian health care practitioners regarding primary prevention of NMSC.
Methods: Structured literature searches were conducted, using search terms including prevention, sunscreen, and sun prevention factor.
Background: The 2006 Canadian Dermatology Association (CDA) member survey tracked the Canadian dermatology workforce. Information on use of nondermatologist extenders, impact of financial burden on practice style, and wait times was collected in the survey.
Objective: To survey Canadian dermatologists for specialty-specific physician resource information including demographics, workload, and future career plans and compare it to results from the 2001 survey.
Background: Alefacept has been demonstrated in clinical trials to be an effective, safe, and well-tolerated treatment strategy when used alone or in combination with other antipsoriatic therapies in patients with chronic plaque psoriasis.
Objective: AWARE (Amevive Wisdom Acquired from Real-World Evidence) is a multicenter, observational, Canadian phase IV registry evaluating the efficacy and safety of alefacept, alone or in combination with other antipsoriatic therapies, in patients with psoriasis.
Methods: Patients with chronic plaque psoriasis were treated with at least one course of alefacept followed by an off-treatment period, typically lasting 12 or more weeks.
Background: Evidence from clinical trials supports the use of alefacept for the treatment of patients with chronic plaque psoriasis, either as monotherapy or combined with other treatment modalities.
Objective: AWARE (Amevive Wisdom Acquired from Real-World Evidence) is a multicenter, observational, phase IV Canadian registry of psoriasis patients treated with alefacept.
Methods: Patients with chronic plaque psoriasis were treated with at least one course of alefacept treatment followed by a period of at least 12 weeks off-treatment.
Background: Alefacept has demonstrated efficacy in clinical trials of patients with chronic plaque psoriasis, either as monotherapy or combined with other treatment modalities such as phototherapy.
Objective: AWARE (Amevive Wisdom Acquired from Real-World Evidence) is a multicenter, observational, phase IV Canadian registry of psoriasis patients treated with alefacept.
Methods: Patients with chronic plaque psoriasis were treated with at least one course of alefacept, either alone or added on to their existing antipsoriatic treatment regimen.
Background: Alefacept was the first biologic therapy approved by Health Canada for the treatment of moderate to severe chronic plaque psoriasis and is used either alone or as part of combination therapy.
Objective: AWARE (Amevive Wisdom Acquired from Real-World Evidence) is a multicenter, observational phase IV Canadian study of psoriasis patients treated with alefacept. This study's main goals were to develop a shared, real-time, national clinical database to support best practice and optimize the care of patients receiving alefacept and to gain an understanding of how alefacept is used in Canadian clinical practice.
Purpose: To provide the specialist in skin and wound care with evidence-based guidelines for care of the person with a diabetic foot ulcer.
Target Audience: This continuing education activity is intended for physicians and nurses with an interest in wound care and related disorders.
Objectives: After reading this article and taking this test, the reader should be able to: 1.
Background: Hidradenitis suppurativa (HS) is a recurrent disease confined to apocrine gland-bearing areas causing painful, deep-seated lesions and draining sinus tracts. Uniformly effective therapy is lacking. Improvements in current medical management strategies are needed.
View Article and Find Full Text PDFObjective: To survey Canadian dermatologists for specialty-specific physician resource information including demographics, workload and future career plans.
Background And Methods: In 2001, the Canadian Dermatology Association (CDA) surveyed 555 dermatologists in Canada to gain specialty-specific physician resource information. Three hundred and seventy-one dermatologists (69%) provided information about themselves, their workloads and their future career goals.